Timing of androgen deprivation therapy: some questions answered, others not.
Schellhammer
Paul F
PF
D000368:Aged; D000726:Androgen Antagonists / Q000191:economics / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000191:economics / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D006278:Medicare; D008875:Middle Aged; D010819:Physician's Role; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000639:trends; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy; D018714:Radiotherapy, Adjuvant; D012720:Severity of Illness Index; D015996:Survival Rate; D013997:Time Factors; D014481:United States
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal